CAR T-cells in hematologic malignancies: Advances, challenges, and future directions

Area of Science:

• Hematologic Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematologic malignancy treatment.
• CAR T-cells redirect T lymphocytes to target tumor-associated antigens like CD19 and TNFRSF17, overcoming conventional therapy resistance.
• This therapy shows high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma.

Purpose of the Study:

• To review the transformative impact and ongoing advancements in CAR T-cell therapy for hematologic malignancies.
• To discuss the evolution of CAR design and its effect on efficacy and safety.
• To highlight current challenges and future directions for improving CAR T-cell therapy.

Main Methods:

• Review of pivotal trials and real-world evidence on CAR T-cell therapy outcomes.
• Analysis of CAR design optimization strategies, including armored and logic-gated platforms.
• Examination of emerging strategies like multi-antigen targeting and in vivo delivery.

Main Results:

• CAR T-cell therapy demonstrates durable responses in various hematologic cancers.
• Optimized CAR designs have enhanced T-cell persistence, specificity, and safety.
• Challenges persist, including cytokine release syndrome, neurotoxicity, manufacturing, cost, and access.

Conclusions:

• CAR T-cell therapy is a pillar of precision hematologic oncology, with ongoing innovation driving improvements.
• Emerging strategies and technologies like AI and point-of-care manufacturing promise to enhance efficacy and scalability.
• Continued research is crucial for overcoming limitations and expanding global access to CAR T-cell therapy.